Trade-Ideas: Abbott Laboratories (ABT) Is Today's Post-Market Leader Stock
Trade-Ideas LLC identified
(
) as a post-market leader candidate. In addition to specific proprietary factors, Trade-Ideas identified Abbott Laboratories as such a stock due to the following factors:
- ABT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $440.0 million.
- ABT is up 3.8% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in ABT with the Ticky from Trade-Ideas. See the FREE profile for ABT NOW at Trade-Ideas
More details on ABT:
Abbott Laboratories manufactures and sells health care products worldwide. The stock currently has a dividend yield of 2.5%. ABT has a PE ratio of 3. Currently there are 12 analysts that rate Abbott Laboratories a buy, no analysts rate it a sell, and 4 rate it a hold.
The average volume for Abbott Laboratories has been 11.2 million shares per day over the past 30 days. Abbott has a market cap of $61.9 billion and is part of the health care sector and health services industry. The stock has a beta of 1.48 and a short float of 3.7% with 6.01 days to cover. Shares are down 6.3% year-to-date as of the close of trading on Monday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Abbott Laboratories as a
. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and a generally disappointing performance in the stock itself.
Highlights from the ratings report include:
- The current debt-to-equity ratio, 0.41, is low and is below the industry average, implying that there has been successful management of debt levels. Although the company had a strong debt-to-equity ratio, its quick ratio of 0.88 is somewhat weak and could be cause for future problems.
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 86.2% when compared to the same quarter one year ago, falling from $2,292.00 million to $316.00 million.
- Net operating cash flow has significantly decreased to -$93.00 million or 4750.00% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- You can view the full Abbott Laboratories Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.